CGT

102개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved102 programs
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD19.CAR-aNKT cells (CD19.CAR-aNKT cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Small Lymphocytic Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

CD22 CAR-transduced T cells (CD22 CAR-transduced T cells)

Acute Lymphoblastic Leukemia; B-All · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCenter for International Blood …Phase 2

CD33CART allogeneic (CD33CART allogeneic)

Acute Myelogenous Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Institute of Allergy a…Phase 2

CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT (CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT)

X-Linked Combined Immunodeficiency Diseases · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSt. Jude Children's Research Ho…Phase 1

Autologous (CD70-CAR T cell infusion, CD70-CAR T cell infusion (Autologous))

Hematologic Malignancy; ALL, Childhood · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intrapleural (CEA-targeted CAR-T, CEA-targeted CAR-T (Intrapleural))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Intravenous (CEA-targeted CAR-T, CEA-targeted CAR-T (Intravenous))

NSCLC (Advanced Non-small Cell Lung Cancer); Breast Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Calmhome Cell and Gene …Preclinical

CHT102 allogeneic CAR T cells (CHT102 allogeneic CAR T cells)

Mesothelin Positive Tumors · Mesothelin Positive Tumors

#MesothelinPositiveTumors#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells (Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells)

Difficult to Treat Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleAllotera TherapeuticsPreclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEver Supreme Bio Technology Co.…Phase 2

HLA-G-CAR.BiTE allogeneic γδ T cells (HLA-G-CAR.BiTE allogeneic γδ T cells)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSouth Valley UniversityPhase 3

L-carnitine (L-carnitine)

Oligoasthenozoospermia; Male Infertility · Oligoasthenozoospermia

#Oligoasthenozoospermia#CGT#Phase3#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

4 / 6 pages

← PreviousNext →